North China Pharmaceutical, Limited operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares North China Pharmaceutical, Limited with three other
companies in this sector in China:
Shanghai Shyndec Pharmaceutical Co Ltd
sales of 8.52 billion Chinese Renmimbi [US$1.23 billion]
of which 60%
was Drug Products),
Livzon Pharmaceutical Group Incorporated
(8.53 billion Chinese Renmimbi [US$1.23 billion]
of which 43%
was Western Medicine), and
Dong-E-E-Jiao Co Ltd
(7.37 billion Chinese Renmimbi [US$1.06 billion]
of which 87%
was Medicine Manufacturing).
During the year ended December of 2017, sales at
North China Pharmaceutical, Limited were 7.71 billion Chinese Renmimbi (US$1.11 billion).
decrease of 4.6%
versus 2016, when the company's sales were 8.08 billion Chinese Renmimbi.
Contributing to the drop in overall sales was the 51.9% decline
in Medicine and Other Logistics Trade, from 2.20 billion Chinese Renmimbi to 1.06 billion Chinese Renmimbi.
There were also decreases in sales in
Medical Intermediate (down 30.4% to 118.75 million Chinese Renmimbi)
However, these declines were partially offset by the increase in sales of
Chemical Preparation Medicine (up 10.4% to 3.82 billion Chinese Renmimbi)
Chemical Raw Medicine (up 6.2% to 1.77 billion Chinese Renmimbi)
Biopharmacy (up 113.2% to 652.00 million Chinese Renmimbi)
Other Main Operations (up 16.2% to 216.98 million Chinese Renmimbi)